Brain

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®

NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell…

7 months ago

Dana Foundation Recognizes Two Neuroscience & Society Champions with Inaugural Awards

Neuroethicist and psychiatrist are recognized for innovation and transformative interdisciplinary work to advance neuroscience's benefits to society NEW YORK, June…

7 months ago

Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including ‘Neurophet AQUA AD’

Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from Alzheimer's disease treatmentsTo accelerate partnering efforts…

7 months ago

Amendola Earns Three Prestigious Healthcare and Health Tech-Focused PR Awards

SCOTTSDALE, Ariz., June 12, 2025 /PRNewswire/ -- Amendola, an award-winning, insights-driven public relations and marketing firm that is part of…

7 months ago

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),…

7 months ago

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),…

7 months ago

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),…

7 months ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Ra’anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing…

7 months ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Ra’anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing…

7 months ago

Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people…

7 months ago